
NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target
NRX Pharmaceuticals (NRXP) Analyst Ratings
Bulls say
NRX Pharmaceuticals Inc has significantly bolstered its financial position through recent financing activities, enhancing its cash reserves to advance its clinical development and commercialization efforts. The company has expressed confidence in achieving profitability on a run-rate basis by the end of 2025, supported by strategic partnerships and the acquisition of revenue-generating entities, including the anticipated $10 million annual revenue from recent acquisitions. Additionally, NRX-101's demonstrated efficacy in treating bipolar depression with acute suicidal ideation, along with its expanding clinical pipeline and targeted revenue goal of $100 million by 2025, contributes to a favorable outlook for the company's stock.
Bears say
NRX Pharmaceuticals Inc. is projected to significantly reduce its annual operating loss from $27.8 million in 2023 to $18.5 million in 2024, largely attributed to decreased research and development spending. Key risks affecting the company's outlook include the potential failure of ongoing clinical trials, stringent regulatory obligations, and challenges related to product commercialization and market differentiation. Additionally, the company faces uncertainties regarding intellectual property protection and the challenges posed by potential fundraising in unfavorable market conditions.
This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares